Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?

Transaction and post-transaction values based connected SEC Form 4 weighted mean acquisition terms ($26.27).

• How does this merchantability comparison to Jon Congleton's anterior open-market dispositions?
  The 75,000 shares sold transcend the caller median open-market merchantability size of 16,236 shares, and besides the earlier play median of 32,529.5 shares, indicating an uptick successful disposition size comparative to Congleton’s emblematic cadence since August 2023.

• What proportionality of nonstop holdings did the transaction impact, and what remains?
  The merchantability represented 9.61% of Congleton's nonstop holdings astatine the time, leaving 705,051 shares straight held aft the transactions — astir 58.6% of his August 2023 starting position.

• Were immoderate shares disposed of done indirect vehicles oregon derivative instruments?
  No; each shares sold were held directly, with zero indirect oregon derivative information successful this transaction.

* 1-year terms alteration calculated utilizing April 2, 2026 arsenic the notation date.

• Mineralys Therapeutics develops lorundrostat, a proprietary, orally administered aldosterone synthase inhibitor, targeting patients with uncontrolled oregon resistant hypertension.

• The institution operates a clinical-stage biopharmaceutical model, generating worth done the advancement and imaginable commercialization of caller cardiovascular therapies.

• Primary customers see healthcare providers, payers, and patients affected by hypertension and related cardiovascular conditions.

Mineralys Therapeutics is simply a clinical-stage biotechnology institution focused connected innovative therapies for hypertension and cardiovascular disease.

Leveraging a targeted attack with lorundrostat, Mineralys aims to code important unmet needs successful resistant hypertension. The company's strategy centers connected advancing its pipeline done objective development.

CEO Jon Congleton’s March 31 merchantability of 75,000 Mineralys Therapeutics shares is not needfully a informing motion for investors. He executed the transactions arsenic portion of his Rule 10b5-1 trading plan, adopted successful December of 2025.